A positive deal with a $125 target from Raymond James underscores Lilly’s strength:Mounjaro and Zepbound are capturing market share from competitors like Novo Nordisk, with Lilly’s manufacturing capacity (10 million doses annually by 2026) supporting dominance. With obesity and diabetes markets expanding, Lilly’s projected $50 billion in annual revenue by 2030 offers a compelling 15-20% upside for long-term investors.
Amazon is the easiest buy today: AWS’s 31% cloud...
Tesla’s once-explosive growth trajectory appears to be flattening...
Buffett’s 2022 sale of TSMC citing
Amazon is the easiest buy today: AWS’s 31% cloud...
Tesla’s once-explosive growth trajectory appears to be flattening...
Buffett’s 2022 sale of TSMC citing
Eli Lilly’s Blockbuster Drug Growth in Q3 2023
testtest news
Eli Lilly’s Blockbuster Drug Growth in Q3 2023
Massive AI Expansion Across Creative Cloud Massive AI Expansion Across Creative Cloud
Eli Lilly’s Blockbuster Drug Growth in Q3 2023
Amazon is a top pick for a decade-long hold
